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Response surface methodologyTheaimof this studywas to develop andoptimizeTrimetazidine dihydrochloride (TM) controlled
porosity osmotic pump (CPOP) tablets of directly compressed cores. A 23 full factorial designwas
used to study the inﬂuence of three factors namely: PEG400 (10%and 25%basedon coating poly-
merweight), coating level (10%and20%of tablet coreweight) andhole diameter (0 ‘‘no hole’’ and
1 mm). Other variables such as tablet cores, coating mixture of ethylcellulose (4%) and dibu-
tylphthalate (2%) in 95% ethanol and pan coating conditions were kept constant. The responses
studied (Yi) were cumulative percentage released after 2 h (Q%2h), 6 h (Q%6h), 12 h (Q%12h) and
regression coefﬁcient of release data ﬁtted to zero order equation (RSQzero), forY1,Y2,Y3, andY4,
respectively. Polynomial equations were used to study the inﬂuence of different factors on each
response individually. Response surface methodology and multiple response optimization were
used to search for an optimized formula. Response variables for the optimized formula were
restricted to 10% 6 Y1 6 20%, 40% 6 Y2 6 60%, 80% 6 Y3 6 100%, andY4 > 0.9. The statis-
tical analysis of the results revealed that PEG400 had positive effects on Q%2h, Q%6h and
Q%12h, hole diameter had positive effects on all responses and coating level had positive effect
on Q%6h, Q%12h and negative effect on RSQzero. Full three factor interaction (3FI) equations
were used for representation of all responses except Q%2h which was represented by reduced
(3FI) equation. Upon exploring the experimental space, no formula in the tested range could sat-
isfy the required constraints. Thus, direct compression of TMcores was not suitable for formation
of CPOP tablets. Preliminary trials of CPOP tablets with wet granulated cores were promising
with an intact membrane for 12 h and high RSQzero. Further improvement of these formulations
to optimize TM release will be done in further studies.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Controlled drug delivery has taken an important position in
pharmaceutical development due to improving the tolerability
and patient compliance with prescribed dosing regimens [1].
Despite the extensive use of polymer-based systems,
348 B.A. Habib et al.alternatives have been developed to decrease the inﬂuence of
the different physiological factors affected by food intake
and patient age [2]. Osmotic drug delivery systems use osmotic
pressure as an energy source and driving force for delivery of
drugs. Presence of food, pH, and other physiological factors
may affect drug release from most controlled release systems
(matrices and reservoirs), whereas drug release from oral os-
motic systems is independent of these factors to a large extent
[3].
The controlled porosity osmotic pump tablets (CPOP tab-
lets) concept was developed by many researchers as an oral
drug delivery system [4,5]. This CPOP tablet is a spray-coated
tablet with a semipermeable membrane coat containing leach-
able pore former materials [6]. In this system, the drug, after
dissolution in the core, is released from the osmotic pump tab-
let by hydrostatic pressure and diffusion through pores created
by the dissolution of pore formers incorporated in the mem-
brane. The hydrostatic pressure is created by an osmotic agent,
the drug itself or a tablet component, after water is imbibed
across the semipermeable membrane [7].
Trimetazidine dihydrochloride (TM) is a metabolic anti-
ischemic drug which improves myocardial and muscles glucose
utilization [8]. It is used in the prophylaxis against and man-
agement of angina pectoris, in cases of ischemia of neurosenso-
rial tissues and also in Meniere’s disease [9]. It is rapidly
absorbed, and its half-life is relatively short (t1/
2 = 6.0 ± 1.4 h) [9]. Being a freely water soluble drug, it will
be a challenging task to formulate it in a controlled release
drug delivery system. The direct compression technique was
used to prepare the tablet cores.
Direct Compression of tablets is the easiest way of process-
ing tablets. It includes the main steps of powder blending,
lubrication, and compaction. As there is no granulation step
to improve the ﬂow and compaction of ingredients, it is usually
necessary to use excipients speciﬁcally designed for direct com-
pression and engineered to provide the necessary ﬂow and
compaction properties [10].
23 factorial design was adopted in this study. Factorial de-
signs are of the most efﬁcient designs for experiments involving
the study of the effects of two or more factors. By a factorial
design, we mean that in each complete trial or replication of
the experiment, all possible combinations of the levels of the
factors are investigated [11]. Optimization technique based
on a response surface methodology (RSM) using polynomial
equations [12,13] enables the navigation of the experimental
space and ﬁnding the optimized formula with predetermined
constraints for multiple factors. This optimization technique
will be used to search for the optimal TM zero order ex-
tended-release formulation for a period of 12 h.
The aim of this study was to answer the question: Can TM




Trimetazidine dihydrochloride, Sharon Bio-Medicine, India;
spray dried lactose, Molkerei MEGGLE Wasserburg GmbH
& Co., KG, Germany; microcrystalline cellulose (avicel PH-
102), F M C Biopolymer, Ireland and PEG400, BASF FineChemicals, Switzerland, were kind gift samples from Global
Napi Pharmaceuticals Company. Magnesium stearate, Witco
Corp, USA. Ethylcellulose, viscosity of 5% solution in tolu-
ene/ethanol 80:20 is 100 cP, extent of labeling: 49% ethoxyl,
Sigma–Aldrich Chemie, Steinhiem, Germany. Dibutylphtha-
late, Sigma–Aldrich Company, St. Louis, USA. All other
chemicals were of the analytical grade and used as received.
Experimental design for CPOP tablets of directly compressed
cores
Three independent variables expected to have pronounced ef-
fects on the osmotic release of TM from CPOP tablets of di-
rectly compressed cores were investigated [14]. Each factor
was studied at two levels; hence, a 23 full factorial design
was applied [11]. The levels of these parameters vary widely
in different researches of osmotic formulations. These speciﬁc
levels were chosen based on the wide ranges used in other stud-
ies and on preliminary trials for formation of continuous coat.
Other variables such as tablet cores, other coating compo-
nents, and coating conditions were kept constant. The inde-
pendent variables (factors) and their respective levels
investigated together with the dependent variables (responses)
and their constraints are shown in Table 1. These dependent
variables constraints were used for obtaining a desirable drug
release as described in literature [13,15]. These required con-
straints choice was based on the desired zero order release pro-
ﬁle. The cumulative percentage of drug released was
considered to be 0% at 0 h, and the ideal drug release was sup-
posed to be 90% in 12 h. Therefore, the equation of zero order
release is F(%) = 7.5 t where F(%) is the cumulative percent-
age released of drug, and t is the release time in hours [16].
Substitution with the required times for responses (2, 6, and
12 h) yielded the results of (15%, 45%, and 90%, respectively).
The constraints were set by giving a range for each response
around its calculated value. Setting the Y2 between 40% and
60% was to allow for about 50% of the drug to be released
after half the release period. Y4 (which is the regression coefﬁ-
cient of release data ﬁtted to zero order release equation) was
chosen to be maximized to ensure ﬁtting of the release data to
zero order release kinetics.
The preparation of the tablets according to suggested trials
as well as the release studies were done in random order. Each
combination was performed twice in two separate replicates
giving a total of sixteen runs. The trials listed in standard order
[11] are shown in Table 2.
Preparation of tablet cores
Tablet cores of 300 mg each were prepared. Each tablet core
contained: 35 mg TM, 131 mg spray dried lactose, 131 mg
microcrystalline cellulose (avicel PH-102), and 3 mg magne-
sium stearate.
Aliquots corresponding to 125 g powder blend (passed
through sieve #40) except magnesium stearate were geometri-
cally mixed in a plastic bag. Finally, magnesium stearate was
passed through sieve #60 and added to the previous blend just
before tabletting.
The bulk density of the powder blend containing magne-
sium stearate was determined using a tapped density tester (Er-
weka Type: SVM202, Erweka, Germany). The lift height was
Table 1 Factors and respective levels investigated in the 23 design together with the responses and their constraints.
Factors Levels investigated
Low (1) High (+1)
X1: PEG400 (%) 10 25
X2: Coating level (%) 10 20
X3: Hole diameter (mm) 0 1
Responses Constraints
Y1 = cumulative% drug released in 2 h (Q%2h) 10% 6 Y1 6 20%
Y2 = cumulative% drug released in 6 h (Q%6h) 40% 6 Y2 6 60%
Y3 = cumulative% drug released in 12 h (Q%12h) 80% 6 Y3 6 100%
Y4 = R
2 (Regression coeﬃcient of release data ﬁtted to zero order equation) (RSQzero) Maximize (>0.9)
Table 2 The composition and observed responses of the 23 factorial design with trials listed in the standard order of this design.
Trial Factors Responses
X1 X2 X3 Y1 (Q%2h) Y2 (Q%6h) Y3 (Q%12h) Y4 (RSQzero)
D1 10 10 0 0.5 1.6 2.8 0.975
D2 25 10 0 0.5 68.5 100.0 0.864
D3 10 20 0 0.6 1.8 54.6 0.560
D4 25 20 0 0.8 70.7 100.0 0.880
D5 10 10 1 1.4 4.9 18.6 0.857
D6 25 10 1 31.4 87.9 100.0 0.761
D7 10 20 1 0.5 77.0 100.0 0.904
D8 25 20 1 26.5 82.7 99.5 0.831
where X1: PEG400 (%), X2: Coating level (%), and X3: Hole diameter (mm).
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were calculated.
The powder blend was then directly compressed using a sin-
gle punch tablet machine (Korsch XP1, Korsch, Germany)
using 9 mm deep concave punch and die set.
Evaluation of tablet cores
The tablet cores were evaluated for the different physicochem-
ical parameters, viz. appearance, weight variation, diameter,
thickness, hardness, friability (Tablet friabilator, Digital test
apparatus, Model DFI-1, Veego, Bombay, India) and drug
content [14,17].
Coating and drilling
Tablet cores were coated using pan coating technique [18–20],
with a ﬂow of hot air to aid the coalescence of coating material
droplets. The coating polymer of choice was ethylcellulose 4%
w/w in ethyl alcohol (95%) [16,21]. Ethylcellulose was soaked
in ethanol and stirred on a magnetic stirrer for 12 h. Dibu-
tylphthalate (2% w/w) was then added. PEG400 was added
as a pore former [18,22] in a speciﬁed amount (10% or 25%)
based on polymer weight [16,21] for controlling membrane
porosity. The coating was carried out by coating pan having
a diameter of 20 cm attached to a drive motor. The rotating
speed was kept at 12 rpm. The spraying mixture was sprayed
using a spray gun ﬁtted to an air compressor. The pan and tab-
let cores were preheated to 40 C before spraying the coating
mixture. Spraying of the coating mixture was continuously
done at a rate of (1.5 ml/min) with a ﬂow of hot air. Coatingprocess was continued till tablets acquire the desired increase
in weight [19,22]. Tablets were subjected to thermal after treat-
ment (curing) for 2 h at 60 C [14,17,23]. One hole of the de-
sired size (1 mm) was mechanically drilled on one face of
each tablet if needed [18,20]. This hole aimed at increasing
the release rate from the early time of dissolution as the drug
solution can exit through the hole as well as from the pores
in the membrane [6].In vitro release studies
The release of TM from the coated tablets was performed in
USP paddle dissolution tester (USP Dissolution Tester, Appa-
ratus II, Varian VK7000, Varian Inc., North Carolina, USA).
Two-steps dissolution test [24] was carried out to simulate the
physiological condition of GIT. In order to detect the drug re-
lease levels in the initial hours, the volume of release medium
was reduced [14]. The release medium was 300 ml 0.1 N HCl
for 2 h, then 100 ml of 0.2 M tribasic sodium phosphate solu-
tion were added to the dissolution medium and pH adjusted to
6.8 ± 0.05 with 2 N HCl or 2 N NaOH if needed [25], and the
dissolution experiment was continued till a total period of 12 h
(pH meter, Jenway 3510 pH meter, Barlworld scientiﬁc Ltd.,
UK). The temperature was maintained at 37.5 ± 0.5 C, and
the paddle speed was set at 100 rpm [14,24]. Aliquots of 3 ml
from the dissolution medium were withdrawn at speciﬁed time
points and ﬁltered. The same volume of fresh medium was re-
placed after each sample withdrawal [22]. All release studies
were done in duplicates. The amount of TM dissoluted was
measured spectrophotometrically at k= 231 nm (UV/VIS
Spectrophotometer, UV-1601, Shimadzu, Japan) against the
350 B.A. Habib et al.respective medium as blank. Although the maximum wave-
length of trimetazidine is 269 nm, it has another absorption
maximum at 231 nm. The wavelength of 231 nm was chosen
in our study as trimetazidine spectrophotometric absorptivity
is much higher at 231 nm than at 269 nm, to enable the detec-
tion of low trimetazidine concentrations.
The drug concentration values were corrected for progres-
sive dilution to obtain cumulative amount permeated using
the following equation [26].
Q0tðnÞ ¼ Vr:Cn þ Vs:
X
Cm
Cumulative% released ¼ Q0tðnÞ:100=dose
where Q0tðnÞ is the current cumulative mass of drug dissoluted at
time t, Cn represents the current concentration in the dissolu-
tion medium, R Cm denotes the summed total of the previous
measured concentrations [m= 1 to n  1], Vr is the volume of
the dissolution medium, Vs corresponds to the volume of the
sample removed for analysis, and dose is the amount of drug
per tablet (35 mg).
The in vitro release data obtained were plotted as the cumu-
lative percentage drug released as a function of time (hour)
[18,22].
Statistical analysis of the 23 factorial results
Design-Expert software (V. 7.0.0, Stat-Ease Inc., Minneapolis,
USA) was used for the evaluation of the statistical experimen-
tal design. Means were compared by ANOVA-factorial. Sig-
niﬁcance level was set at a= 0.05. Suitable regression
models were driven to enable navigation of the experimental
space [27]. Response surface methodology and multiple re-
sponse optimization were used to search for an optimized for-
mula [13].
Results and discussion
Osmotic pumping is the primary mechanism of drug release
from the oral osmotic pumps with simple diffusion playing a
minor role [6]. The prepared CPOP tablets are spray-coated
tablets with a semipermeable membrane coat containing leach-
able pore former material (PEG400). Upon contact with the
release medium, this pore former leaches out leaving a micro-
porous structure in the membrane. Water enters through the
membrane, where it dissolves the water soluble components
(TM and spray dried lactose). Hydrostatic pressure is created
between the core of the tablet and the release medium. The lac-
tose diluent as an osmogen helps in increasing this hydrostatic
pressure. Most soluble sugars and salts function effectively for
this purpose [19]. In this system, the drug after dissolution in
the core is released from the CPOP tablets by hydrostatic pres-
sure and diffusion through the pores created in the membrane
and the drilled hole if any [7]. This drug release rate is usually
controlled by the coat thickness, pore former percentage, core
osmogen content, and hole size. In the present study, the cores
composition was kept constant, as the drug is freely water sol-
uble and the diluents contain 50% lactose, which together cre-
ate enough osmotic pressure for water entrance. The studied
variables were coat thickness, pore former percentage, and
hole size.Dibutylphthalate was used by Makhija and Vavia [14] to
control membrane porosity in a concentration of 20% w/w
of the used coating polymer (cellulose acetate). Garg et al.
[28] used dibutylphthalate in a concentration of 0.6% of total
coating mixture as a plasticizer for the cellulose acetate coat. In
the present study, dibutylphthalate was added as a plasticizer
in a concentration of 2% of total coating mixture (50% of
the ethylcellulose polymer) as a constant variable to aid the
membrane forming properties of ethylcellulose. This helped
in forming continuous good adhering membranes even at
low PEG400 concentration. Higher concentrations of dibu-
tylphthalate were not used to avoid sticking between tablets
during coating. Triethyl citrate and PEG1500 were tried in pre-
liminary experiments of this study as alternative plasticizers,
yet dibutylphthalate was chosen for its better ﬁlm forming
properties.
A thermal after treatment (curing) was applied to obtain
sufﬁcient polymer particle coalescence in the membrane
[23,29]. If the polymer particles do not completely fuse during
coating, further coalescence may occur during storage, result-
ing in denser and less permeable membranes. Consequently,
the resulting drug release rate may signiﬁcantly decrease on
storage.
In vitro evaluation of tablet cores
Bulk density was found to be 0.494 g/ml, while the tap den-
sity = 0.635 g/ml. Carr’s compressibility index was found to
be 22.2% and Hausner ratio was found to be 1.285, indicating
passable ﬂowability.
Tablet cores showed acceptable weight variation of
302.12 mg ± 8.8, acceptable drug content of 35.03 mg ±
0.33, acceptable friability of 0.048%, and hardness value of
4.74 kg ± 0.207. These parameters were suitable for further
work [30].In vitro release results for CPOP tablets of directly compressed
cores
In general, an optimal extended release dosage form must
have a minimal burst effect with most of the drug being re-
leased in a speciﬁc time period [12]. Therefore, the percent-
age of drug released after 2 h (Q%2h), 6 h (Q%6h), and 12 h
(Q%12h) were selected as the response variables. These time
points were used to detect the burst effect at an earlier stage
and to ensure that most of the drug is released in a period
of time suitable to the gastrointestinal residence time.
RSQzero was used as the fourth response to ensure the zero
order release pattern [3]. The constraints of these responses
were speciﬁed to obtain a zero order release proﬁle and per-
centage released of more than 80% in 12 h as shown in Ta-
ble 1. Release proﬁles of the different prepared formulae are
shown in Fig. 1. In Fig. 1, the wide variation indicated that
the investigated factors and their studied levels resulted in
different drug release rates.
The composition of different trials of the 23 factorial design
and their respective observed responses listed in the standard
order of this design are shown in Table 2.


















































Fig. 1 Release proﬁle of TM from different trials, (n= 2),
mean + r.
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Each response was analyzed individually. Full factorial 3 fac-
tor interaction (3FI) model was used to describe the relation
between the response under question and the variables studied.
The general 3FI polynomial equation is as follows:







where Yi is the response under question, Xi’s (for i= 1–3) are
the factors, XiXj (for i, j= 1–3, i< j) are the 2 factor interac-
tions, XiXjXk (for i, j, k= 1–3, i< j< k) are the 3 factor
interactions, b0 the intercept term, bi’s (for i= 1–3) are the lin-
ear effects coefﬁcients, bij’s (for i, j= 1–3, i< j) are the inter-
action coefﬁcients between the ith and jth variables, and bijk
(for i, j, k= 1–3, i< j< k) are the interaction coefﬁcients be-
tween the ith, jth and kth variables.Table 3 R-squared values and PRESS for models of different respo
R2
Y1 Full factorial model 0.9858
Y1 Reduced model (chosen) 0.9754
Y2 Full factorial model 0.9518
Y3 Full factorial model 0.9795
Y4 Full factorial model 0.9912Model reduction [20] was adopted by removing nonsigniﬁ-
cant model terms not required to support hierarchy [31]. For
evaluation of different models, several R2 statistics are calcu-
lated, namely, ordinary R2, adjusted R2, and predicted R2
[13]. The model chosen either full or reduced was the one with
the highest prediction R2 and the lowest prediction error sum
of squares (PRESS) [12]. Summary of R2 statistics and PRESS
for models of different responses is shown in Table 3. For Y1, a
certain reduced model showed higher prediction R2 and lower
PRESS than the full factorial model. This reduced model was
the model of choice for this response. For the other responses,
all the possible reduced models did not produce any improve-
ment. The full factorial models were chosen for these re-
sponses. Table 4 shows the coefﬁcient estimates for different
model terms appearing in the ﬁnal equation for each response
and their signiﬁcance levels.
Inference of the statistical analysis of the different responses in
the 23 design
The coefﬁcient estimate of each term is half the effect of that
term, whether this term is a main effect or a 2 factor interac-
tion. Thus, the main effect of each factor on different re-
sponses will be discussed. Also, each 2 factor interaction for
different responses will be discussed [27].
Effect of PEG400%
Percentage of PEG400 had a signiﬁcant positive effect on the
Q%2h, Q%6h, and Q%12h. That is the higher the PEG400%
the higher the percentage of the drug released after 2 h, 6 h,
and 12 h, respectively. This could be explained by the water sol-
uble nature of this pore former. Since PEG400 is a hydrophilic
plasticizer, the higher the PEG400% the more the void space
formed in the membrane after PEG400 leaching which results
in higher permeability of themembrane allowing higher inﬂuxes
of water and solubilization of TM then exit of TM solution to
the release medium. This is in accordance with the results found
inmany other researches. Xu et al. [22] stated that the salvianolic
acid release rate increased from a microporous cellulose acetate
membrane as the pore forming substance (PEG400) increased.
Lu et al. [18] stated that the increase in PEG400 level led to an
increase in naproxen release rate from controlled porosity osmo-
tic pump coatedwith PEG400 plasticized cellulose acetatemem-
brane.Makhija andVavia [14] stated that as the amount of PEG
400 in the cellulose acetate polymeric coat increased, pseudoe-
phedrine release rate also increased.
Effect of coating level%
Coating level% had a signiﬁcant positive effect on Q%6h and
Q%12h. That is the higher the value of coating level% thenses.






Table 4 Coefﬁcient estimates for different model terms appearing in the ﬁnal equation for each response and their signiﬁcance levels.
Y1 Y2 Y3 Y4
CE p-Value CE p-Value CE p-Value CE p-Value
b0 7.79 <0.0001
* 49.38 <0.0001* 71.93 <0.0001* 0.829 <0.0001*
b1 7.03 <0.0001
* 28.07 <0.0001* 27.95 <0.0001* 0.005 0.2184
b2 – – 8.66 0.0177
* 16.59 <0.0001* 0.035 <0.0001*
b3 7.18 <0.0001
* 13.73 0.0015* 7.59 0.0048* 0.009 0.0432*
b12 – – 9.44 0.0118* 16.71 <0.0001* 0.057 <0.0001*
b13 6.97 <0.0001
* 5.9 0.0774 7.71 0.0044* 0.047 <0.0001*
b23 – – 8.06 0.0244
* 3.64 0.1011 0.065 <0.0001*
b123 – – 9.92 0.0092* 3.76 0.0922* 0.051 <0.0001*
CE: Coefﬁcient estimate.
* Signiﬁcant at p< 0.05.
352 B.A. Habib et al.higher the values of Q%6h and Q%12h. This is in contrary to
the results found in many other studies. Xu et al. [22] stated
that the salvianolic acid release rate from a microporous mem-
brane was affected by and was inversely proportional to over-
all coating weight. Makhija and Vavia [14] stated that as the
polymer loading (coating level) of cellulose acetate polymeric
coat increased, pseudoephedrine release rate decreased. They
explained this by the fact that the ﬂuid had to penetrate the
polymer coat of greater thickness as the polymer loading in-
creased. Liu and Xu [21] found that nifedipine release rate de-
creased as the PEG400 plasticized ethylcellulose membrane
thickness increased. They reported that the increase in thick-
ness led to increase in the membrane resistance to water pene-
tration, resulting in a decrease in the drug release rate. Lu et al.
[18] stated that the increase in membrane thickness had no sig-
niﬁcant difference on naproxen release rate from controlled
porosity osmotic pump coated with PEG400 plasticized cellu-
lose acetate membranes. The difference between the thick-
nesses of membranes used in that research was explained by
them to be not enough to signiﬁcantly change the release
proﬁles.
In the present work, we suggest that the elasticity of the
membrane coat decreased as its thickness increased. On en-
trance of water into the tablet core, the avicel present in the
core imbibes water and tends to increase in volume. In the
presence of a thicker coat, the coat cracked, leading to a higher
release of TM solution through the cracks formed resulting
into higher Q%6h and Q%12h. This explanation is also sup-
ported by the nonsigniﬁcant effect of coating level for the re-
sponse Q%2h. That is because there had not been any
cracks yet in the membrane to allow higher ﬂuxes of TM solu-
tion from the core. These cracks were large enough to be ob-
served with naked eye.
Coating level% had a signiﬁcant negative effect on
RSQzero. That is as the coat thickness increases, the release
proﬁle becomes less ﬁtting to zero order release mechanism.
This may be due to the higher possibility of cracks formation
on thicker membranes which disturbed zero order release
proﬁle.
Effect of hole diameter
The two levels studied for hole diameter were 0 that is no hole
and 1 mm. Generally, hole presence in CPOP tablets is not a
must due to the in situ formed micro-pores after the leaching
of pore forming material. Yet, a lag time usually appears inthe release proﬁle due to time taken for coat hydration and
PEG400 leaching. Presence of an extra hole was thought to
overcome this delay in drug release initiation.
Hole diameter had a signiﬁcant positive effect on Q%2h,
Q%6h, and Q%12h. This could be explained by the presence
of an opening for direct water entrance. This allows higher in-
ﬂux of water and solubilization then exit of TM solution to the
release medium in higher amounts through this opening. This
is in accordance with the results found by Prabakaran et al. [6].
The presence of the hole had also a signiﬁcant positive ef-
fect on RSQzero as it resulted in direct water entrance and less
lag time before acquiring a near zero order drug release proﬁle.
Interaction of PEG400% and coating level%
Response surface plots for the effects of PEG400% and coat-
ing level% on different responses are shown in Fig. 2. A neg-
ative signiﬁcant interaction occurred between PEG400% and
coating level% for the responses Q%6h and Q%12h. This
may be due to the cracks formed in the membrane at higher
coating level which resulted in higher release even with lower
PEG400%. This explanation is also supported by the absence
of this interaction for the response Q%2h as no cracks in the
membrane were yet formed.
A positive signiﬁcant interaction occurred between
PEG400% and coating level% for the response RSQzero. At
higher PEG400% level, higher inﬂuxes of water were achieved
from the beginning of release process, which compensated for
the cracks formed after some time in the release, which resulted
in increase in the value of this response. That is this positive
interaction led to a more ﬁtting of the release proﬁle to the zero
order release mechanism.
Interaction of PEG400% and hole diameter
Response surface plots for the effects of PEG400% and hole
diameter on different responses are shown in Fig. 3. A positive
signiﬁcant interaction occurred between PEG400% and hole
diameter for the response Q%2h. That is the effect of
PEG400% on Q%2h increased by increasing the hole diameter.
This could be explained by the increased water entry through
the hole in the early stages of release resulting into an increase
in the amount of TM diffused after 2 h.
On the other hand, a negative signiﬁcant interaction oc-
curred between PEG400% and hole diameter for the response
Q%12h. After 12 h, PEG400 had completely dissolved and
Fig. 2 Response surface plot for the effect of PEG400% and
coating level% on different responses: (a) Q%6h, (b) Q%12h, and
(c) RSQzero.
Optimizing trimetazidine release from controlled porosity osmotic pump tablets 353enough openings had formed and the presence of the hole did
not have a pronounced effect on release.Also, a negative signiﬁcant interaction occurred between
PEG400% and hole diameter for the response RSQzero. This
could be explained by the positive interaction of these vari-
ables after 2 h (Q%2h) and their negative interaction after
12 h (Q%12h) as previously mentioned. These opposite direc-
tions interactions may have led to a less linear release
proﬁle.
Interaction of coating level% and hole diameter
Response surface plots for the effects of coating level% and
hole diameter on different responses is shown in Fig. 4. A po-
sitive signiﬁcant interaction occurred between coating level%
and hole diameter for the response Q%6h. That is the effect
of coating level% on Q%6h increased in presence of the hole.
This could be due to higher water inﬂuxes on higher hole diam-
eter, higher volume of avicel in the core after water imbibition,
and more cracks formation in thicker coats which led to higher
TM release.
A positive signiﬁcant interaction between coating level%
and hole diameter for the response RSQzero was also noticed.
This may be due to faster and more cracks formation in pres-
ence of the hole which resulted into reduced lag time.
Elucidation of an optimized formula for TM release
The constraints listed in Table 1 were used for numerical
optimization of a formula with the desired responses by
the aid of the statistical program. The tested trials resulted
into a wide range of responses; Q%2h ranged from
0.504% to 31.447%, Q%6h from 1.562% to 87.934%,
Q%12h from 2.7825% to 99.99%, and RSQzero from
0.5596 to 0.97495. Unfortunately, upon exploring the exper-
imental space, no speciﬁc formula in the tested ranges of the
independent variables could satisfy the required constraints.
The release proﬁles of the tested formulae showed either a
lag time of 0.5 h to 2 h and then very rapid release rates
(formulae D2, D4, D6, D7, and D8), a very low release rate
for the whole 12 h (formulae D1 and D5) or a very long lag
time of about 7 h then high release rate (formula D3). This
may be due to the presence of avicel as a component of tab-
let cores. At low levels of water entrance, the TM release
was low and the coat remained intact for the whole 12 h.
At high levels of water entrance, avicel imbibes high
amounts of water, and its disintegrant nature led to cracks
formation in the coat, which disturbed the zero release pro-
ﬁle characteristic of osmotic release formulae.
The present study aimed at testing the feasibility of
using the direct compression technique to prepare TM tab-
let cores for CPOP tablets. Direct compression is consid-
ered the easiest technique for tablet production. Direct
compression of tablet cores for formation of osmotic re-
lease oral drug delivery systems have been used by many
researchers [16,29,33]. This technique showed good results
especially with the use of expandable polymers in the core
formulation [3,20,33].
In preliminary experiments performed early in the present
work, spray dried lactose and mannitol were used each alone
as a diluent for formation of directly compressed tablet
cores. Yet, the ﬂuffy nature of TM powder hindered the di-
rect compression of tablet cores with both diluents. The
Fig. 3 Response surface plot for the effect of PEG400% and hole diameter on different responses: (a) Q%2h, (b) Q%6h, (c) Q%12h, and
(d) RSQzero.
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garded as one of the best excipients having high binding
capacity in directly compressed cores [12]. So, in the present
study, it was used with spray dried lactose in a ratio 1:1 to
aid direct compression of TM tablet cores. The cores pre-
pared with avicel and lactose acquired suitable hardness
and friability and were satisfactory for coating, so the 23 de-
sign was initiated and the suggested CPOP tablets were
prepared.
The prepared tablets failed to fulﬁll the required release
proﬁle of TM. This was due to disintegrant nature of avicel
which led to cracks in the coat that is supposed to remain
intact for the whole release period of 12 h. The cracks
formed in coat also led to ﬂuctuation of drug release in
some trials. This is thought to be due to the ununiformity
of cracks formed. However, microcrystalline cellulose had
been used by some workers for formulation of osmotic tab-
lets [24,32,34].
To recapitulate, the direct compression of CPOP tablets
cores – under the studied conditions especially the use of avicelin the core – was found to be not suitable for optimizing TM
release.
In an attempt to use lactose monohydrate as a sole soluble
diluent for formation of tablet cores suitable for optimizing
TM release from CPOP tablets, wet granulation technique
was tried. This was to avoid cracks formation in the coat,
and keeping the coat intact for the whole release period of
12 h. Preliminary trials of CPOP tablets of these wet granu-
lated cores were subjected to release studies. Although the per-
centages released from these trial formulations did not meet
the constraints listed in Table 1, yet these formulations ap-
peared to be promising with an intact membrane for 12 h
and high RSQzero. Further improvement of these formulations
to optimize TM release will be done in further studies. The
improvements on these formulations will include changing dib-
utylphthalate and PEG400 concentrations, coat thickness, and
hole size. A new statistical design with new levels of factors will
be used for optimizing trimetazidine release from CPOP tab-
lets of wet granulated cores according to the same constraints
of the present study.
Fig. 4 Response surface plot for the effect of coating level% and
hole diameter on: (a) Q%6h, (b) Q%12h, and (c) RSQzero.
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The results of the statistical analysis revealed that PEG400%
had a signiﬁcant positive effect on Q%2h, Q%6h, and Q%12h.
Coating level% had a signiﬁcant positive effect on Q%6hand Q%12h and a signiﬁcant negative effect on RSQzero. Hole
diameter had a signiﬁcant positive effect on Q%2h, Q%6h,
Q%12h, and RSQzero.
Unfortunately, upon exploring the experimental space, no
formula in the tested range of variables could satisfy the re-
quired constraints. (10% 6 Y1 6 20%, 40% 6 Y2 6 60%,
80% 6 Y3 6 100%, and Y4: Maximize > 0.9). This may be
due to the presence of avicel as a component of tablet cores.
The disintegrant nature of avicel led to cracks formation in
the coat on high water entrance, which disturbed the zero order
release proﬁle characteristic of CPOP formulae. Thus, TM re-
lease could not be optimized from the prepared CPOP formulae
of directly compressed cores under the studied conditions.
Preliminary trials of CPOP tablets of wet granulated cores
using lactose monohydrate as a sole diluents were promising
with an intact membrane for 12 h and high RSQzero. Further
improvement of these formulations to optimize TM release
will be done in further studies.
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